Aclarion Inc. (ACON), which makes AI-augmented tools for diagnosing chronic lower back pain, delivered a progress report Thursday that had investors pretty excited. The company is seeing real commercial traction for its Nociscan platform, the kind of growth that suggests doctors are actually finding this technology useful rather than just interesting.

Scan Volumes Tell the Growth Story

Here's the headline number: fourth-quarter scan volumes shot up 114% compared to the same period last year. That's not a typo. Annual volumes rose 69% year-over-year, marking three straight quarters of growth across facilities in the U.S., U.K., and Europe.

During 2025, Aclarion brought nine new imaging centers online and added 22 physician users to its network. The company also expanded its commercial and leadership teams on both sides of the Atlantic, building out the infrastructure to support continued scaling.

The Clinical Evidence Is Stacking Up

Beyond just selling more scans, Aclarion is methodically building the evidence base that payers and physicians need to see. The company launched its CLARITY trial in 2025 with seven sites now active, and management expects to have roughly 25% of patients enrolled by the end of Q2 2026, with an internal interim data readout planned for Q3.

Meanwhile, published research is making the economic case pretty compelling. A cost-effectiveness analysis in ClinicoEconomics and Outcomes Research found that Nociscan beats provocative discography on both effectiveness and cost, saving $1,712 per patient while boosting surgical success rates by 10%. Additional real-world evidence and technical overviews appeared in the International Journal of Spine Surgery, giving the platform growing academic credibility.

Financial Runway Looks Solid

As of December 31, 2025, Aclarion had $12 million in cash and zero debt. The company raised more than $22 million in equity financing during the year, extending its operating runway into the first half of 2027. That gives management breathing room to execute on clinical milestones without immediate funding pressure.

"We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption," CEO Brent Ness said.

Aclarion shares jumped 55.13% to $8.92 in premarket trading Thursday as investors digested the update.